Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (1934${count})

  • Therapeutic Pipeline Program, 2020
    Novel Candidate against Alpha-synuclein for the Treatment of Parkinson’s Disease

    Study Rationale:
    The goal of this program is to develop a novel drug for Parkinson’s disease with a unique mechanism of action. We have a drug candidate that shows potential as an inhibitor of alpha...

  • Biosample Use Program, 2020
    Identification of Autoantibodies in People at Risk of Developing Parkinson’s Disease Using Microarrays

    Study Rationale:    
    Autoantibodies are antibodies that mistakenly target and react with a person's own tissues or organs. Autoantibodies can be detected many years before symptoms develop in many...

  • Research Grant, 2020
    GBA Variations, Cholinergic Degeneration, and Cognitive Decline in Parkinson’s Disease

    Study Rationale:
    Mutations in the GBA gene are the most common genetic risk factors for Parkinson’s disease. People with GBA mutations (GBA-PD) may develop the disease at a younger age and may have...

  • Research Grant, 2020
    Safety and Tolerability of NLX-112 in People with Parkinson’s

    Study Rationale:
    Motor symptoms of Parkinson’s disease are caused by a lack of brain neurons that carry a neurotransmitter called dopamine, and are commonly treated with levodopa. However, after...

  • Research Grant, 2020
    Parkinson’s Disease Subtyping by Genetic and Intestinal Inflammation Biomarkers

    Study Rationale: 
    Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. Currently, no drugs are available to treat or prevent the disease because the processes...

  • Biosample Use Program, 2020
    Single-molecule Detection of Oligomeric Synuclein in Body Fluids

    Study Rationale:
    Clumps, or aggregates, of the protein alpha-synuclein have been detected in spinal fluid of people with Parkinson’s disease, where its concentration shows potential to be a biomarker...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.